WuXi CDS is a wholly-owned subsidiaries of WuXi AppTec in China. We offer comprehensive Phase I – IV clinical development services for pharmaceuticals, biologics, and medical devices. We specialize in helping bring innovative, breakthrough products to market – a process that demands stringent quality control and experienced professionals from Phase I through to final submission. WuXi CDS also offers flexible, customized strategic solutions – professionals who deliver services right from our clients’ offices, supporting specific tasks or helping ride out the peaks and troughs inherent in clinical development project timelines
|Industry||Discovery Chemistry, ADME/DMPK, Formulation, and Bioanalysis|
|Number of employees||10,001+ employees|
Established in December 2000, WuXi AppTec (NYSE: WX) is oneof the leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States.
WuXi AppTec has successfully established a fully integrated services and technology platform during the past decade. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.
WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 10,000 employees and 5 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services both in China and in the U.S., WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.
Uniquely positioned, they provide a bridge between China and the global marketplace:
They help international companies:
Bring innovative medical products into the challenging regulatory environment of China
Access the world’s largest patient pool with the goal of helping patients by developing innovative treatments for the most prevalent diseases, such as cancer, diabetes, and cardiovascular disease.
They also help local Chinese companies:
Launch their medical products onto the competitive, highly-regulated global pharmaceutical marketplace.
- Regulatory Affairs
- Medical & Scientific Writing
- Medical Advisory & Monitoring
- Clinical Operations
- Early Clinical
- Data Management, Statistical Analysis & Drag Safety
Top 5 Recent Tweets
Top 5 Recent News Headlines
Notice of WuXi PRA Renamed as WuXi CDS
In Dec. 2015, WuXiPRA, a joint venture CRO established in December 2012 by WuXi Apptec and PRA Health Sciences, has decided to conduct business and equity restructuring due to strategic development considerations. The restructuring was completed in 18th Mar. 2016, and WuXiPRA was renamed as WuXi CDS (WuXi Clinical Development Services (Shanghai) Co., Ltd.), and became a wholly owned subsidiary of WuXi Apptec.
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines